deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01112384

A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas (IND200)

A Phase II Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Sponsor: NCIC Clinical Trials Group

Conditions Metastatic Sarcoma
Interventions SB939
Updated 8 times since 2017 Last updated: Aug 3, 2023 Started: Oct 21, 2010 Primary completion: Jan 21, 2013 Completion: Jan 16, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01112384, this PHASE2 trial focuses on Metastatic Sarcoma and remains completed. Sponsored by NCIC Clinical Trials Group, it has been updated 8 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Apr 2020 · 22 months · monthly snapshotCompleted~Apr 2020 – ~May 2020 · 30 days · monthly snapshotCompleted~May 2020 – ~Jan 2021 · 8 months · monthly snapshotCompleted~Jan 2021 – ~Sep 2023 · 32 months · monthly snapshotCompleted~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Sep 2023 [monthly]

    Completed PHASE2

  5. May 2020 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Apr 2020 — May 2020 [monthly]

    Completed PHASE2

  2. Jun 2018 — Apr 2020 [monthly]

    Completed PHASE2

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NCIC Clinical Trials Group
  • S*BIO
Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations